AstraZeneca plc (AZN) Given Buy Rating at Bryan, Garnier & Co
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reiterated by analysts at Bryan, Garnier & Co in a research report issued to clients and investors on Monday. They currently have a GBX 5,220 ($64.60) target price on the biopharmaceutical company’s stock. Bryan, Garnier & Co’s price target indicates a potential upside of 5.52% from the stock’s previous close.
Several other equities research analysts also recently commented on AZN. BNP Paribas downgraded shares of AstraZeneca plc to a “neutral” rating and set a GBX 5,200 ($64.36) price objective for the company. in a research note on Wednesday, September 14th. HSBC reissued a “hold” rating and set a GBX 4,700 ($58.17) target price on shares of AstraZeneca plc in a report on Thursday, August 11th. Beaufort Securities reissued a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, August 10th. Societe Generale set a GBX 7,000 ($86.63) target price on shares of AstraZeneca plc and gave the stock a “buy” rating in a report on Thursday, September 8th. Finally, Sanford C. Bernstein set a GBX 5,168 ($63.96) target price on shares of AstraZeneca plc and gave the stock a “neutral” rating in a report on Friday, July 29th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of GBX 4,960.13 ($61.39).
AstraZeneca plc (LON:AZN) opened at 4920.50 on Monday. The company’s market cap is GBX 62.24 billion. The firm’s 50 day moving average is GBX 4,994.73 and its 200 day moving average is GBX 4,473.20. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/astrazeneca-plc-azn-given-buy-rating-at-bryan-garnier-co.html
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.